Journal: Cell Death & Disease

Article Title: Dual-faced metabolic reprogramming powers proliferation: FGF21 drives lung squamous carcinoma progression via CaMKII-DRP1-mediated mitochondrial fission

doi: 10.1038/s41419-026-09084-3

Figure Lengend Snippet: A Representative Western blotting images showing the expression of mitochondrial fusion and fission proteins in response to FGF21 treatment. The protein levels were normalized to the GAPDH levels. B Representative Western blotting images showing the expression of p-DRP1 Ser616 and DRP1. C Immunofluorescence staining showing the expression level of p-DRP1 Ser616; scale bars, 100 μm. Fiji software was used for image analysis, and the average fluorescence intensity was calculated. D Fractions of LUSC cell lysates, showing the levels of DRP1 in the mitochondrial (Mito) and cytoplasmic (Cyto) fractions. The mitochondrial protein COX-IV and the cytoplasmic protein β-actin served as controls. E Confocal microscopy images showing the levels of mitochondria-bound DRP1 in LUSC cells treated with FGF21. DRP1 and mitochondria were labeled with a mouse anti-DRP1 antibody and Mito Tracker Green, respectively; scale bars, 10 μm (annotation added; original software-generated scale bar displayed a “too long” error due to a display glitch). Pearson’s coefficient indicates colocalization of DRP1 and Mito Tracker Green. The data are shown as the means ± SEMs or SDs; * p < 0.05, ** p < 0.01, *** p < 0.01.

Article Snippet: Anti-p-DRP1 (ser616) , 4494 , Rabbit , CST , WB (1:1000); IF (1:1000).

Techniques: Western Blot, Expressing, Immunofluorescence, Staining, Software, Analysis, Fluorescence, Confocal, Microscopy, Labeling, Generated

Journal: Cell Death & Disease

Article Title: Dual-faced metabolic reprogramming powers proliferation: FGF21 drives lung squamous carcinoma progression via CaMKII-DRP1-mediated mitochondrial fission

doi: 10.1038/s41419-026-09084-3

Figure Lengend Snippet: A Representative western blotting images showing the protein expression of p-CaMKII (Thr286) in H1703 and H520 cells incubated with FGF21 for different durations. B Representative Western blotting images showing the protein expression of p-CaMKII (Thr286), CaMKII, p-DRP1 (Ser616) and DRP1 in H1703 and H520 cells incubated with FGF21 pretreated with KN93. C Immunofluorescence staining showing the expression and distribution of p-DRP1 (Ser616) and DRP1 in H1703 and H520 cells incubated with FGF21 pretreated with KN93. D Immunofluorescence staining showing the mitochondrial morphology in H1703 and H520 cells incubated with FGF21 pretreated with KN93. E CCK-8 assay showing the viability of H1703 and H520 cells incubated with FGF21 pretreated with or without KN93. F Representative western blotting images showing the expression of key glycolytic pathway components (GLUT1, LDHA) in DRP1-silenced LUSC cells with or without FGF21 stimulation. GAPDH served as a loading control. The data are shown as the means ± SEMs or SDs; * p < 0.05, ** p < 0.01, *** p < 0.01, **** p < 0.01.

Article Snippet: Anti-p-DRP1 (ser616) , 4494 , Rabbit , CST , WB (1:1000); IF (1:1000).

Techniques: Western Blot, Expressing, Incubation, Immunofluorescence, Staining, Morphology, CCK-8 Assay, Control

Journal: Cell Death & Disease

Article Title: Dual-faced metabolic reprogramming powers proliferation: FGF21 drives lung squamous carcinoma progression via CaMKII-DRP1-mediated mitochondrial fission

doi: 10.1038/s41419-026-09084-3

Figure Lengend Snippet: List of primary antibodies, secondary antibodies, and nuclear dyes used in this study.

Article Snippet: Anti-p-DRP1 (ser616) , 4494 , Rabbit , CST , WB (1:1000); IF (1:1000).

Techniques: